explore -WSS

explore

author：hotspot 2025-09-06 03:56:22 - browse：43364

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： ASCO Takeaways: Winners, snoozers, and the art of cancer care

knowledge

WSS

Eli Lilly’s Zepbound improved liver scarring in mid

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

CMS got Medicare Advantage quality rating wrong, judge rules

For pregnant people, addiction treatment shouldn't mean a call to child protective services

FDA clears AI tool for detecting skin cancer

Think you might have Covid

leisure time

explore

knowledge

Alkermes shareholders re

An outdated Medicare rule harms dementia patients with anxiety

Moonlake's readout produced a cash windfall. Risks remain

eGenesis tests gene

In Memoriam: Notable people who died in 2023

Stopping antidepressants leads to symptoms for 1 in 6 patients

Cancer drug shortages should be causing more outrage

EU regulator recommends expanding Mounjaro approval to obesity

Medicare proposal to cover medical devices draws a mixed reaction

Independent physicians launch a new lobbying group

hotspot

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Humana cuts profit projections as Medicare Advantage costs soar

Fight over Supreme Court dialysis ruling puts kidney patients at risk

AI generated plenty of interest at JPM but not a lot of trust

Biotech venture capitalists face new demands from investors

The most pressing bird flu mysteries scientists want answered

Wikipedia

knowledge

leisure time

leisure time